More News

Boost in cancer fight as mini-antibodies reactivate p53 protein

Jim Cornall -
Each year, 20m people are diagnosed with cancer. Various organs can be affected, and cancer types differ greatly at...

Scientists discover new way to make drug-resistant cancer treatable

Jim Cornall -
Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most...

KAIST identifies viruses and variants simultaneously by controlling CRISPR speed​

Jim Cornall -
As the spread of infectious diseases accelerates, technologies that can accurately distinguish multiple viruses in a single test are...

Base to Base biotech podcast 57: Keeping drugs cool, and treatment resistant depression

Jim Cornall -
This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher,...

ELREXFIO improves progression-free survival for patients with relapsed or refractory multiple myeloma

Jim Cornall -
Pfizer Inc. has announced positive topline results from the phase 3 MagnetisMM-5 study evaluating ELREXFIO (elranatamab) as monotherapy in...

Aragen launches India’s first women-led chemistry synthesis laboratory

Jim Cornall -
Aragen, a contract research, development, and manufacturing organisation (CRDMO) has launched ChemiSHE, a first-of-its-kind chemistry synthesis laboratory in India,...

Vaccine strategy induces broadly neutralising HIV antibodies

Jim Cornall -
Researchers at Karolinska Institutet in Sweden, in collaboration with colleagues at The Scripps Research Institute and Emory University, have...

New target for cancer treatment

Jim Cornall -
Scientists have uncovered an unexpected way cells can generate cancer-driving proteins—by cutting RNA into shorter, functional fragments rather than...

Researchers identify key protein in inflammatory response to infections

Jim Cornall -
Whenever there is a wound or infection, the body produces an inflammatory response. This is the body’s first line...

Experimental drug protects body from harmful effects of gluten

Jim Cornall -
An experimental drug may provide a new form of protection for people with coeliac disease. According to an international...

Japanese pharma companies shifting to earlier CDMO outsourcing

Jim Cornall -
Japanese pharmaceutical companies are engaging contract development and manufacturing organisations (CDMOs) earlier in the development cycle, as increasing complexity...

Promising cell model for dementia research

Jim Cornall -
Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases – with potential...

Antibodies offer hope for autoimmune diseases

Jim Cornall -
The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens. While operation of...

New lung cancer model reveals tumour location shapes the immune response

Jim Cornall -
Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside...

ADHD-related traits may intensify chronic pain

Jim Cornall -
Chronic pain evades common treatments and affects millions of people around the world. Pain is not a purely physical...

Hidden mechanism in DNA damage

Jim Cornall -
For decades, researchers have studied how oxidative stress affects DNA and have found that guanine, one of its four...

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall -
This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel...

Positive first-in-human data for IVF-related embryo implantation failure treatment

Jim Cornall -
Freya Biosciences has announced positive topline results from its phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain...

New company plans to replace daily injections with implant

Jim Cornall -
RBL LLC has launched Duracyte, a biotechnology company commercialising a pioneering class of implantable "biohybrid pharmacy" devices designed to...

UCB adds epilepsy drug through Neurona Therapeutics acquisition

Jim Cornall -
UCB has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding...

Mechanism ‘opens new era’ for targeted cancer therapy

Jim Cornall -
Penetrium Bioscience has announced new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism...